CN109963864B - 用于亲和色谱的碱性稳定性fc结合蛋白 - Google Patents

用于亲和色谱的碱性稳定性fc结合蛋白 Download PDF

Info

Publication number
CN109963864B
CN109963864B CN201780050413.2A CN201780050413A CN109963864B CN 109963864 B CN109963864 B CN 109963864B CN 201780050413 A CN201780050413 A CN 201780050413A CN 109963864 B CN109963864 B CN 109963864B
Authority
CN
China
Prior art keywords
binding
protein
ala
gln
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780050413.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109963864A (zh
Inventor
P·柯尼克
E·菲德勒
U·豪普茨
M·梅兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ripley Gold
Original Assignee
Ripley Gold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ripley Gold filed Critical Ripley Gold
Priority to CN202311795884.XA priority Critical patent/CN117736281A/zh
Publication of CN109963864A publication Critical patent/CN109963864A/zh
Application granted granted Critical
Publication of CN109963864B publication Critical patent/CN109963864B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26—Synthetic macromolecular compounds
    • B01J20/262—Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2221/00—Applications of separation devices
    • B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CN201780050413.2A 2016-08-11 2017-08-07 用于亲和色谱的碱性稳定性fc结合蛋白 Active CN109963864B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311795884.XA CN117736281A (zh) 2016-08-11 2017-08-07 用于亲和色谱的碱性稳定性fc结合蛋白

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16183710.9 2016-08-11
EP16183710 2016-08-11
EP16205707.9 2016-12-21
EP16205707 2016-12-21
PCT/EP2017/069979 WO2018029158A1 (en) 2016-08-11 2017-08-07 Alkaline stable fc—binding proteins for affinity chromatography

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311795884.XA Division CN117736281A (zh) 2016-08-11 2017-08-07 用于亲和色谱的碱性稳定性fc结合蛋白

Publications (2)

Publication Number Publication Date
CN109963864A CN109963864A (zh) 2019-07-02
CN109963864B true CN109963864B (zh) 2024-01-02

Family

ID=59631752

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780050413.2A Active CN109963864B (zh) 2016-08-11 2017-08-07 用于亲和色谱的碱性稳定性fc结合蛋白
CN201780044905.0A Active CN109476712B (zh) 2016-08-11 2017-08-07 新型对碱稳定的免疫球蛋白结合蛋白
CN202210871980.7A Pending CN116333065A (zh) 2016-08-11 2017-08-07 新型对碱稳定的免疫球蛋白结合蛋白
CN202311795884.XA Pending CN117736281A (zh) 2016-08-11 2017-08-07 用于亲和色谱的碱性稳定性fc结合蛋白

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201780044905.0A Active CN109476712B (zh) 2016-08-11 2017-08-07 新型对碱稳定的免疫球蛋白结合蛋白
CN202210871980.7A Pending CN116333065A (zh) 2016-08-11 2017-08-07 新型对碱稳定的免疫球蛋白结合蛋白
CN202311795884.XA Pending CN117736281A (zh) 2016-08-11 2017-08-07 用于亲和色谱的碱性稳定性fc结合蛋白

Country Status (11)

Country Link
US (4) US11014967B2 (enExample)
EP (4) EP3497117B1 (enExample)
JP (3) JP6951417B2 (enExample)
KR (3) KR20230133943A (enExample)
CN (4) CN109963864B (enExample)
AU (2) AU2017311541B2 (enExample)
CA (2) CA3030208A1 (enExample)
DK (1) DK3497117T5 (enExample)
LT (1) LT3497117T (enExample)
SG (1) SG11201901066UA (enExample)
WO (2) WO2018029157A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
CN107922483B (zh) 2015-07-16 2021-07-30 纳维格蛋白质有限公司 新型免疫球蛋白结合蛋白及其在亲和纯化中的用途
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
CN109310780A (zh) 2016-05-04 2019-02-05 纳维格蛋白质有限公司 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物
AU2017311541B2 (en) * 2016-08-11 2020-08-13 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
EP3546476A1 (en) * 2018-03-26 2019-10-02 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
JP7355729B2 (ja) 2017-08-07 2023-10-03 レプリゲン・コーポレイション Ｃ末端ヘリカル領域にシステインを有するｆｃ結合タンパク質
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
EP4249097A3 (en) * 2018-02-01 2024-01-10 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
EP3650465A1 (en) 2018-11-12 2020-05-13 Navigo Proteins Gmbh Novel populations of polypeptides having a triple-helical structure
SG11202103139PA (en) * 2018-11-12 2021-04-29 Navigo Proteins Gmbh Novel triple-helical polypeptides lacking binding affinity for the fc domain of immunoglobulin and uses thereof
US20220112236A1 (en) * 2019-02-01 2022-04-14 Navigo Proteins Gmbh Immunoglobulin binding proteins for affinity purification
GB201904125D0 (en) 2019-03-26 2019-05-08 Ge Healthcare Bio Sciences Ab Method for sanitization of a chromatography column
JP7432813B2 (ja) * 2019-09-10 2024-02-19 東ソー株式会社 免疫グロブリン結合性タンパク質
JP7689746B2 (ja) * 2019-12-17 2025-06-09 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 酵素酸性αグルコシダーゼ（ＧＡＡ）の結合タンパク質及びその使用
EP4107178B1 (en) * 2020-02-21 2024-01-10 Navigo Proteins Gmbh Affinity ligand for the soluble part of fibroblast growth factor receptor 3 (sfgfr3)
EP3875472A1 (en) * 2020-03-06 2021-09-08 Navigo Proteins Gmbh Novel immunoglobulin binding polypeptides
CA3183655A1 (en) * 2020-06-23 2021-12-30 Mathias KAHL Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2)
EP4132943B1 (en) * 2020-07-15 2024-05-29 Navigo Proteins Gmbh Immunoglobulin binding proteins for affinity purification
EP4240487A1 (en) * 2020-11-09 2023-09-13 Navigo Proteins Gmbh Novel type ii collagen binding proteins
EP4001301A1 (en) * 2020-11-13 2022-05-25 Navigo Proteins Gmbh Binding protein for complement factor h (cfh)
WO2023012321A1 (en) * 2021-08-06 2023-02-09 Roche Diagnostics Gmbh Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides
CN114591407B (zh) * 2021-12-21 2023-07-04 百林科(兰州)新材料有限公司 耐碱蛋白a变体及其应用
CN113999294B (zh) * 2021-12-30 2022-03-29 苏州纳微科技股份有限公司 免疫球蛋白结合蛋白及其应用
CN114409748A (zh) * 2022-01-28 2022-04-29 博格隆(浙江)生物技术有限公司 蛋白a的b结构域和z结构域突变体及其应用
GB202203478D0 (en) 2022-03-14 2022-04-27 Cytiva Bioprocess R & D Ab Vh3 binding polypeptides
KR20250112269A (ko) * 2022-12-16 2025-07-23 나피고 프로타인스 게엠베하 친화성 크로마토그래피를 위한 신규한 리간드
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
EP4541444A1 (en) * 2023-10-20 2025-04-23 Cytiva BioProcess R&D AB Fusion protein for affinity capture

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522278A (zh) * 2006-09-29 2009-09-02 通用电气健康护理生物科学股份公司 用于抗体分离的包含来自金黄色葡萄球菌a蛋白的结构域c的层析配体
EP2557157A1 (en) * 2010-03-24 2013-02-13 Kaneka Corporation Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand
CN105377880A (zh) * 2013-07-10 2016-03-02 通用电气健康护理生物科学股份公司 突变的免疫球蛋白结合多肽
WO2016079034A1 (en) * 2014-11-17 2016-05-26 Ge Healthcare Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
EP0729513B1 (en) * 1994-07-21 2004-06-02 Aventis Pasteur Limited Analog of haemophilus hin47 with reduced protease activity
US5958684A (en) 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
WO1998054312A1 (en) 1997-05-28 1998-12-03 Babraham Institute Ribosome complexes as selection particles for in vitro display and evolution of proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030045681A1 (en) 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DK1719528T3 (da) 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
US6799121B2 (en) 2000-03-30 2004-09-28 York University Sequencing of peptides by mass spectrometry
US20110179531A1 (en) 2000-05-09 2011-07-21 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
AU2003210802B2 (en) * 2002-02-05 2009-09-10 Genentech Inc. Protein purification
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US20040043386A1 (en) 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
CA2544764A1 (en) 2003-11-04 2005-05-19 Yale University Protein binding miniature proteins
WO2005059131A2 (en) 2003-12-11 2005-06-30 Yale University Protein binding miniature proteins and uses thereof
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
JP2006304633A (ja) * 2005-04-26 2006-11-09 Apro Life Science Institute Inc イムノグロブリン結合タンパク質
DE602006012667D1 (de) 2005-05-11 2010-04-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
DE502005009389D1 (de) 2005-11-09 2010-05-20 Morphosys Ag Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
MX2008013575A (es) 2006-05-08 2008-11-04 Philogen Spa Citoquinas dirigidas a anticuerpos para terapia.
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
HRP20150425T1 (hr) 2008-07-21 2015-06-05 Apogenix Gmbh Tnf sf jednolanäśane molekule
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
KR101436222B1 (ko) 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법
US10065995B2 (en) * 2011-03-25 2018-09-04 Kaneka Corporation Protein for affinity-separation matrix
SG186552A1 (en) * 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
US9492572B2 (en) 2011-06-15 2016-11-15 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
US20150183846A1 (en) 2012-06-13 2015-07-02 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
EP2899271B1 (en) 2012-09-21 2018-07-25 Kaneka Corporation Protein ligand for affinity isolation matrix
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
EP3253795B1 (en) 2015-02-06 2019-04-17 Navigo Proteins Gmbh Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
CN107922483B (zh) 2015-07-16 2021-07-30 纳维格蛋白质有限公司 新型免疫球蛋白结合蛋白及其在亲和纯化中的用途
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
WO2017013129A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Her2 binding proteins based on di-ubiquitin muteins
CN109310780A (zh) 2016-05-04 2019-02-05 纳维格蛋白质有限公司 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物
AU2017311541B2 (en) * 2016-08-11 2020-08-13 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
JP7355729B2 (ja) 2017-08-07 2023-10-03 レプリゲン・コーポレイション Ｃ末端ヘリカル領域にシステインを有するｆｃ結合タンパク質
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
EP4249097A3 (en) 2018-02-01 2024-01-10 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522278A (zh) * 2006-09-29 2009-09-02 通用电气健康护理生物科学股份公司 用于抗体分离的包含来自金黄色葡萄球菌a蛋白的结构域c的层析配体
EP2557157A1 (en) * 2010-03-24 2013-02-13 Kaneka Corporation Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand
CN105377880A (zh) * 2013-07-10 2016-03-02 通用电气健康护理生物科学股份公司 突变的免疫球蛋白结合多肽
WO2016079034A1 (en) * 2014-11-17 2016-05-26 Ge Healthcare Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fc段受体结合蛋白（SPA-SPG）基因克隆表达及其在IgG纯化中的应用;孟照辉等;《生物化学与生物物理进展》;20041231;第31卷(第2期);146-148 *

Also Published As

Publication number Publication date
AU2017311542B2 (en) 2021-06-24
WO2018029158A1 (en) 2018-02-15
AU2017311541A1 (en) 2019-02-21
KR102578256B1 (ko) 2023-09-15
EP3497117B1 (en) 2024-01-24
US20190177376A1 (en) 2019-06-13
EP3497117A1 (en) 2019-06-19
JP2019531055A (ja) 2019-10-31
SG11201901066UA (en) 2019-03-28
AU2017311542A1 (en) 2019-02-07
EP4324840A2 (en) 2024-02-21
EP4177260A1 (en) 2023-05-10
CA3030208A1 (en) 2018-02-15
US11014967B2 (en) 2021-05-25
CN109476712B (zh) 2022-08-02
KR20190044059A (ko) 2019-04-29
WO2018029157A1 (en) 2018-02-15
US20210206815A1 (en) 2021-07-08
AU2017311541B2 (en) 2020-08-13
JP6951417B2 (ja) 2021-10-20
CN116333065A (zh) 2023-06-27
US20190300568A1 (en) 2019-10-03
DK3497117T5 (da) 2024-09-02
KR20190038560A (ko) 2019-04-08
CA3031858A1 (en) 2018-02-15
CN109963864A (zh) 2019-07-02
EP3497118B1 (en) 2022-09-14
JP7181612B2 (ja) 2022-12-01
CN117736281A (zh) 2024-03-22
CN109476712A (zh) 2019-03-15
DK3497117T3 (da) 2024-04-22
EP4324840A3 (en) 2024-04-24
KR102573370B1 (ko) 2023-09-01
JP2022160444A (ja) 2022-10-19
LT3497117T (lt) 2024-05-10
JP2019527715A (ja) 2019-10-03
US20250051400A1 (en) 2025-02-13
US11230576B2 (en) 2022-01-25
KR20230133943A (ko) 2023-09-19
EP3497118A1 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
CN109963864B (zh) 用于亲和色谱的碱性稳定性fc结合蛋白
US12257530B2 (en) Fc binding proteins with cysteine in the c-terminal helical region
US20210054044A1 (en) Fc binding proteins with cysteine in the c-terminal helical region
EP4132943B1 (en) Immunoglobulin binding proteins for affinity purification
US20220112236A1 (en) Immunoglobulin binding proteins for affinity purification
CN120359236A (zh) 亲和色谱的新配体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant